Search PLR Articles Directory Saint Vincent and the Grenadines: March 2009

Sunday, March 22, 2009

Enison

Enison may be available in the countries listed below.

Ingredient matches for Enison

Vindesine

Vindesine sulfate (a derivative of Vindesine) is reported as an ingredient of Enison in the following countries:

Spain

International Drug Name Search

Gliquidon LPH

Gliquidon LPH may be available in the countries listed below.

Ingredient matches for Gliquidon LPH

Gliquidone

Gliquidone is reported as an ingredient of Gliquidon LPH in the following countries:

Romania

International Drug Name Search

Saturday, March 14, 2009

Cypafly

Cypafly may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Cypafly

Cypermethrin

Cypermethrin is reported as an ingredient of Cypafly in the following countries:

Australia

International Drug Name Search

Thursday, March 12, 2009

Adofen

Adofen may be available in the countries listed below.

Ingredient matches for Adofen

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Adofen in the following countries:

Spain

International Drug Name Search

Monday, March 9, 2009

Burnamycin Topical

Generic Name: lidocaine and prilocaine (Gingival route)

LYE-doe-kane, PRIL-oh-kane

Commonly used brand name(s)

In the U.S.

Oraqix

Available Dosage Forms:

Gel/Jelly

Therapeutic Class: Anesthetic, Amino Amide Combination

Chemical Class: Amino Amide

Uses For Burnamycin

Lidocaine and prilocaine periodontal (gingival) gel is used on the gums to cause numbness or loss of feeling during dental procedures. This medicine contains a mixture of two topical local anesthetics (numbing medicines). It deadens the nerve endings in the gum.

This medicine is available only with your dentist's prescription.

Before Using Burnamycin

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of lidocaine and prilocaine periodontal gel in the pediatric population. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of lidocaine and prilocaine periodontal gel in the elderly. However, elderly patients are more likely to have age-related kidney or liver problems, which may require caution and an adjustment in the dose for patients receiving lidocaine and prilocaine periodontal gel.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	B	Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of lidocaine

This section provides information on the proper use of a number of products that contain lidocaine. It may not be specific to Burnamycin. Please read with care.

A dentist or other trained health professional will give you this medicine in an office or clinic setting. The medicine is applied to the gums using a special dispenser.

Precautions While Using Burnamycin

It is very important that your dentist check you closely for any problems or unwanted effects that may be caused by this medicine.

This medicine may cause serious types of allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your dentist right away if you have a rash; itching; hoarseness; trouble with breathing; trouble with swallowing; or any swelling of your hands, face, or mouth after you receive the medicine.

This medicine may cause a rare, but serious blood problem called methemoglobinemia. Call your dentist right away if you develop a blue or bluish purple color on the lips, fingernails, or skin, or have headaches, dizziness, fainting, sleepiness, or trouble with breathing after you receive this medicine.

During the time that the gum feels numb, serious injury can occur. Be especially careful to avoid injury until the numbness wears off and you have normal feeling in the area. Avoid foods or liquids that are very hot or very cold. Do not chew gum or food while your mouth feels numb. You may accidentally bite your tongue or the inside of your cheeks.

Burnamycin Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur:

More common

Gum numbness that continues

gum swelling or irritation

nausea

Rare

Itching

hoarseness or trouble with swallowing

rash

shortness of breath

swelling of the eyelids, face, lips, or tongue

tightness in the chest

trouble with breathing

wheezing

Incidence not known

Blue or blue-purple color of lips, fingernails, mouth, or skin

blurred or double vision

convulsions

dark urine

dizziness or drowsiness

fainting

feeling hot, cold, or numb

headache

irregular or fast heartbeat

muscle twitching or trembling

nausea or vomiting

ringing or buzzing in the ears

shortness of breath or troubled breathing

unusual excitement, nervousness, or restlessness

unusual tiredness or weakness

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Bad or bitter taste

headache

mouth pain or soreness

mouth ulcers

tiredness

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Burnamycin Topical side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

Compare Burnamycin Topical with other medications

Anesthesia

Sunday, March 8, 2009

Dermarest

Generic Name: hydrocortisone (Topical application route)

hye-droe-KOR-ti-sone

Commonly used brand name(s)

In the U.S.

Ala-Cort

Ala-Scalp HP

Anusol HC

Aquanil HC

Beta HC

Caldecort

Cetacort

Corta-Cap

Cortagel Extra Strength

Cortaid

CortAlo With Aloe

Corticaine

Corticool Maximum Strength

Cortizone-10

Cortizone-5

Cotacort

Delacort

Dermarest

Dermtex-HC

Foille Cort

Gly-Cort

Hydrozone Plus

Hytone

Instacort-10

Ivy Soothe

IvyStat

Keratol HC

Kericort 10

Lacticare-HC

Locoid

Locoid Lipocream

Medi-Cortisone Maximum Strength

Microcort

Mycin Scalp

Neutrogena T/Scalp

NuCort

Nupercainal HC

Nutracort

Pandel

Pediaderm HC Kit

Preparation H Hydrocortisone

Proctocream-HC

Recort Plus

Sarnol-HC Maximum Strength

Scalacort

Scalpcort

Summer's Eve Specialcare

Texacort

Therasoft Anti-Itch & Dermatitis

U-Cort

Westcort

In Canada

Barriere-Hc

Cortate

Cort-Eze

Cortoderm Mild Ointment

Cortoderm Regular Ointment

Emo-Cort

Emo-Cort Scalp Solution

Hydrocortisone Cream

Novo-Hydrocort

Novo-Hydrocort Cream

Prevex Hc

Sarna Hc

Available Dosage Forms:

Solution

Cream

Spray

Lotion

Ointment

Liquid

Gel/Jelly

Foam

Stick

Paste

Therapeutic Class: Corticosteroid, Weak

Pharmacologic Class: Adrenal Glucocorticoid

Uses For Dermarest

Hydrocortisone topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions. This medicine is a corticosteroid (cortisone-like medicine or steroid).

This medicine is available both over-the-counter (OTC) and with your doctor's prescription.

Before Using Dermarest

Allergies

Pediatric

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of hydrocortisone topical in the pediatric population. However, because of this medicine's toxicity, it should be used with caution. Children may absorb large amounts through the skin, which can cause serious side effects. If your child is using this medicine, follow your doctor's instructions very carefully.

Geriatric

No information is available on the relationship of age to the effects of hydrocortisone topical in geriatric patients.

Interactions with Medicines

Interactions with Food/Tobacco/Alcohol

Proper Use of hydrocortisone

This section provides information on the proper use of a number of products that contain hydrocortisone. It may not be specific to Dermarest. Please read with care.

It is very important that you use this medicine only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause unwanted side effects or skin irritation.

This medicine is for use on the skin only. Do not get it in your eyes. Do not use it on skin areas that have cuts, scrapes, or burns. If it does get on these areas, rinse it off right away with water.

This medicine should only be used for skin conditions that your doctor is treating. Check with your doctor before using it for other conditions, especially if you think that a skin infection may be present. This medicine should not be used to treat certain kinds of skin infections or conditions, such as severe burns.

To use:

Wash your hands with soap and water before and after using this medicine.

Apply a thin layer of this medicine to the affected area of the skin. Rub it in gently.

With the lotion, shake it well before using.

Do not bandage or otherwise wrap the skin being treated unless directed to do so by your doctor.

If the medicine is applied to the diaper area of an infant, do not use tight-fitting diapers or plastic pants unless directed to do so by your doctor.

If your doctor ordered an occlusive dressing or airtight covering to be applied over the medicine, make sure you know how to apply it. Occlusive dressings increase the amount of medicine absorbed through your skin, so use them only as directed. If you have any questions about this, check with your doctor.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

For redness, itching, and swelling of the skin:
- For topical dosage form (cream):
  - Adults—Apply to the affected area of the skin two or three times per day.
  - Children—Apply to the affected area of the skin two or three times per day.
- For topical dosage form (lotion):
  - Adults—Apply to the affected area of the skin two to four times per day.
  - Children—Apply to the affected area of the skin two to four times per day.
- For topical dosage form (ointment):
  - Adults—Apply to the affected area of the skin three or four times per day.
  - Children—Apply to the affected area of the skin three or four times per day.
- For topical dosage form (solution):
  - Adults—Apply to the affected area of the skin three or four times per day.
  - Children—Apply to the affected area of the skin three or four times per day.

Missed Dose

If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using Dermarest

It is very important that your doctor check your or your child's progress at regular visits for any unwanted effects that may be caused by this medicine.

If your or your child's symptoms do not improve within a few days, or if they become worse, check with your doctor.

Using too much of this medicine or using it for a long time may increase your risk of having adrenal gland problems. The risk is greater for children and patients who use large amounts for a long time. Talk to your doctor right away if you or your child have more than one of these symptoms while you are using this medicine: blurred vision; dizziness or fainting; a fast, irregular, or pounding heartbeat; increased thirst or urination; irritability; or unusual tiredness or weakness.

Stop using this medicine and check with your doctor right away if you or your child have a skin rash, burning, stinging, swelling, or irritation on the skin.

Do not use cosmetics or other skin care products on the treated areas.

Dermarest Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Incidence not known

Blistering, burning, crusting, dryness, or flaking of the skin

irritation

itching, scaling, severe redness, soreness, or swelling of the skin

redness and scaling around the mouth

thinning of the skin with easy bruising, especially when used on the face or where the skin folds together (e.g. between the fingers)

thinning, weakness, or wasting away of the skin

Incidence not known

Acne or pimples

burning and itching of the skin with pinhead-sized red blisters

burning, itching, and pain in hairy areas, or pus at the root of the hair

increased hair growth on the forehead, back, arms, and legs

lightening of normal skin color

lightening of treated areas of dark skin

reddish purple lines on the arms, face, legs, trunk, or groin

softening of the skin

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

More Dermarest resources

Dermarest Use in Pregnancy & Breastfeeding
Dermarest Drug Interactions
Dermarest Support Group
15 Reviews for Dermarest - Add your own review/rating

Compare Dermarest with other medications

Anal Itching
Aphthous Stomatitis, Recurrent
Atopic Dermatitis
Dermatitis
Eczema
Gingivitis
Hemorrhoids
Proctitis
Pruritus
Psoriasis
Seborrheic Dermatitis
Skin Rash
Ulcerative Colitis, Active

Saturday, March 7, 2009

Dermarest Cream

Pronunciation: DYE-fen-HYE-dra-meen
Generic Name: Diphenhydramine
Brand Name: Examples include Benadryl and Dermarest

Dermarest Cream is used for:

Temporarily relieving pain and itching associated with insect bites, minor burns, sunburn, minor skin irritations, minor cuts, scrapes, and rashes caused by poison ivy, poison oak, and poison sumac.

Dermarest Cream is an antihistamine. It works by blocking the action of histamine, which reduces the symptoms of an allergic reaction.

Do NOT use Dermarest Cream if:

you are allergic to any ingredient in Dermarest Cream

you use any other medicine that contains diphenhydramine, unless your doctor tells you to

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dermarest Cream:

Some medical conditions may interact with Dermarest Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have porphyria

Some MEDICINES MAY INTERACT with Dermarest Cream. Because little, if any, of Dermarest Cream is absorbed into the blood, the risk of it interacting with another medicine is low.

Ask your health care provider if Dermarest Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dermarest Cream:

Use Dermarest Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Dermarest Cream is for external use only. Avoid contact with the eyes. Do not swallow Dermarest Cream.

Wash and completely dry the affected area. Gently rub the medicine in until it is evenly distributed. Apply to the affected area not more than 3 to 4 times a day.

Wash your hands immediately after using Dermarest Cream.

If you miss a dose of Dermarest Cream and you are using it regularly, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Ask your health care provider any questions you may have about how to use Dermarest Cream.

Important safety information:

Dermarest Cream may cause harm if it is swallowed. If you have taken it by mouth, contact your poison control center or emergency room right away.

If your symptoms do not get better within 7 days, if they get worse, or if they come back, stop using Dermarest Cream and check with your doctor.

Do not use on chickenpox, measles, or on large areas of the body, including large areas of poison ivy, sunburn, or broken, blistered, or oozing skin, unless advised to do so by your doctor.

Dermarest Cream has diphenhydramine in it. Before you start any new medicine, including one used on the skin, check the label to see if it has diphenhydramine in it too. If it does or if you are not sure, check with your doctor or pharmacist.

Dermarest Cream should not be used in CHILDREN younger than 2 years old; safety and effectiveness in these children have not been confirmed.

PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dermarest Cream while you are pregnant. Dermarest Cream is found in breast milk. If you are or will be breast-feeding while you use Dermarest Cream, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Dermarest Cream:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Skin irritation.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Dermarest side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Dermarest Cream may be harmful if swallowed. Symptoms after swallowing Dermarest Cream may include confusion, hallucinations, or loss of consciousness.

Proper storage of Dermarest Cream:

Store Dermarest Cream at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Keep Dermarest Cream out of the reach of children and away from pets.

General information:

If you have any questions about Dermarest Cream, please talk with your doctor, pharmacist, or other health care provider.

Dermarest Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dermarest Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

More Dermarest resources

Dermarest Side Effects (in more detail)
Dermarest Use in Pregnancy & Breastfeeding
Dermarest Drug Interactions
Dermarest Support Group
0 Reviews for Dermarest - Add your own review/rating

Compare Dermarest with other medications

Pain
Pruritus

Friday, March 6, 2009

Oxymorphone Hydrochloride

Class: Opiate Agonists
VA Class: CN101
CAS Number: 357-07-3
Brands: Opana

Abuse Potential

Schedule II controlled substance with abuse liability similar to morphine.^c

Potential for abuse in a manner similar to other legal or illicit opiates.^c Consider abuse potential when prescribing or dispensing oxymorphone extended-release tablets in situations where the clinician or pharmacist is concerned about increased risk of misuse, abuse, or diversion.^c

Intended Uses of Extended-release Tablets

Oxymorphone hydrochloride extended-release tablets are indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.^c

Oxymorphone hydrochloride extended-release tablets are not intended for use as a prn analgesic.^c

Overdose Risk with Improper Administration of Extended-release Tablets

Oxymorphone hydrochloride extended-release tablets are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed.^c

Chewing, crushing, or dissolving the extended-release tablets could result in rapid release and absorption of a potentially fatal dose of oxymorphone.^c

Do not consume alcoholic beverages or prescription or nonprescription preparations containing alcohol during therapy with extended-release tablets.^c Consuming alcohol while receiving extended-release tablets could result in increased plasma concentrations of oxymorphone and a potentially fatal dose of the drug.^c

Introduction

Opiate agonist; phenanthrene derivative.^a ^b ^c ^d ^e

Uses for Oxymorphone Hydrochloride

Acute and Chronic Pain

Relief of moderate to severe pain.^b ^c ^d

Symptomatic relief of moderate to moderately severe pain such as that associated with acute and some chronic medical disorders including renal or biliary colic, acute trauma, postoperative pain, and cancer.^e

Consider around-the-clock dosing of analgesics in the initial stages of acute pain to avoid wide swings in pain and sedation often associated with as-needed dosing regimens.^e

In the management of chronic pain associated with a terminal illness such as cancer, the principal goal of analgesic therapy is to make the patient relatively pain-free while maintaining as good a quality of life as possible.^e

Analgesic therapy must be individualized and titrated according to patient response and tolerance.^b ^c ^d ^e

Extended-release tablets (Opana ER) are used orally for management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.^c The extended-release tablets are not intended for use on an as-needed (“prn”) basis, for preoperative administration to control postoperative pain, for pain in the immediate postoperative period (12–24 hours after surgery) in patients not previously exposed to opiates, or for postoperative pain that is expected to be mild or of short duration.^c Patients who were receiving this preparation prior to surgery may reinitiate such use after they are able to resume oral therapy.^c Extended-release tablets may be used postoperatively if pain is expected to be moderate to severe and persist for an extended period of time.^c

Surgery

Used parenterally as a supplement to anesthesia.^a ^d

Analgesia During Labor

Used parenterally for analgesia during labor.^d

Acute Pulmonary Edema

Used in patients with acute pulmonary edema for its cardiovascular effects and to allay anxiety.^a ^d ^e Should not be used in the treatment of pulmonary edema resulting from a chemical respiratory irritant.^d

Oxymorphone Hydrochloride Dosage and Administration

Administration

Administer orally,^b ^c or by sub-Q, IM, or IV injection.^a ^d

Oral Administration

Administer orally as conventional tablets or extended-release tablets.^b ^c

Administer conventional and extended-release tablets on an empty stomach, at least 1 hour before or 2 hours after food.^b ^c Food affects oral absorption.^b ^c (See Food under Pharmacokinetics.)

Extended-release tablets: Swallow tablets whole; do not divide, crush, or chew.^c Do not administer with alcohol.^c (See Boxed Warning.)

IV Administration

Administer by direct IV injection.^e

When administered IV, an opiate antagonist and facilities for administration of oxygen and control of respiration should be available.^a ^e

Dosage

Available as oxymorphone hydrochloride; dosage expressed in terms of the salt.^b ^c

Give the smallest effective dose as infrequently as possible to minimize the development of tolerance and physical dependence.^a

Individualize dosage according to clinical status of the patient, desired therapeutic effect, degree of existing opiate tolerance, and age and weight; assess dosage at periodic intervals.^b ^c ^d

Reduce dosage in poor-risk patients, in geriatric patients, and in patients receiving other CNS depressants.^a (See Specific Drugs under Interactions)

Avoid abrupt withdrawal from relatively high dosages (e.g., in chronic pain patients) since precipitation of severe abstinence syndrome is likely.^b ^c ^d

Extended-release tablets usually are administered twice daily in 2 equally divided doses; an asymmetric daily dosing regimen (i.e., different dose in the morning than in the evening) may be appropriate in some patients, depending on the pain pattern.^c

Adults

Pain (Oral Treatment)

Conventional Tablets

Oral

Opiate-naive patients: Usually, initiate with 10–20 mg every 4–6 hours as needed.^b Alternatively, use 5 mg every 4–6 hours.^b Do not initiate with doses >20 mg.^b Adjust according to response and tolerance.^b

Switching from Parenteral Oxymorphone to Conventional Tablets

Oral

Calculate the total daily dosage of the parenteral preparation, multiply by a factor of 10 and administer as conventional tablets in 4 or 6 equally divided doses.^b For example, 10 mg of oral oxymorphone hydrochloride given every 6 hours as conventional tablets can be substituted for a total daily IM oxymorphone hydrochloride dosage of 4 mg.^b

Extended-release Tablets

Oral

Opiate-naive patients: Initiate with 5 mg every 12 hours.^c Adjust according to response and tolerance.^c Titrate in increments of 5–10 mg every 12 hours every 3–7 days to provide adequate analgesia.^c

Switching from Conventional Oxymorphone Tablets to Extended-release Tablets

Oral

Calculate the total daily dosage of the conventional preparation and give as extended-release tablets in 2 divided doses at 12-hour intervals.^c

Switching from Parenteral Oxymorphone to Extended-release Tablets

Oral

Calculate the total daily dosage of the parenteral preparation, multiply by a factor of 10 and administer as extended-release tablets in 2 equally divided doses.^c For example, 20 mg of oral oxymorphone hydrochloride given every 12 hours as extended-release tablets can be substituted for a total daily IM oxymorphone hydrochloride dosage of 4 mg.^c

Monitor closely to ensure adequate analgesia and to minimize side effects.^c

Switching from Other Oral Opiates to Extended-release Tablets

Oral

The equivalent total daily dosage of oxymorphone hydrochloride should be calculated based on standard conversion factors suggested by the manufacturer (table below); initiate therapy with oxymorphone hydrochloride extended-release tablets by administering half the calculated dose in 2 divided doses at 12-hour intervals.^c Titrate dosage to provide adequate analgesia.^c

If patients are on a regimen of several opiates, calculate the approximate oral oxymorphone dose for each opiate and add the totals to estimate the total daily oxymorphone hydrochloride dosage.^c

Converting Daily Opiate Dosages to Oxymorphone Hydrochloride Extended-release Tablets (mg/day prior opiate × factor = approximate mg/day oral oxymorphone hydrochloride)c
Prior Opiate	Approximate Oral Equivalent Dose	Factor Oral
Oxymorphone	10 mg	1
Hydrocodone	20 mg	0.5
Oxycodone	20 mg	0.5
Methadone	20 mg	0.5
Morphine	30 mg	0.333

Table to be used only for conversion to oxymorphone extended-release tablets.^c

Refer to published relative potency information, keeping in mind that conversion ratios are only approximate.^c

When converting from methadone to oxymorphone, monitor patients closely. ^c

Pain (Parenteral Routes)

IV

Initially, 0.5 mg.^d Adjust according to response and tolerance.^d

Sub-Q or IM

1–1.5 mg every 4 to 6 hours as necessary.^d

Analgesia During Labor

0.5–1 mg.^d

Prescribing Limits

Adults

Oral

Conventional tablet: Maximum initial dose is 20 mg.^b

Special Populations

Hepatic Impairment

In patients with mild hepatic impairment, initiate with lowest dosage and increase dose slowly.^b ^c ^d (See Contraindications.)

Renal Impairment

In patients with Cl_cr <50 mL/minute, reduce dosage.^b ^c ^d (See Special Populations under Pharmacokinetics.)

Geriatric Patients

Select dosage with caution; use lower than usual initial dosages.^b ^c ^d (See Geriatric Use under Cautions and see Special Populations under Pharmacokinetics.)

Cautions for Oxymorphone Hydrochloride

Contraindications

Known hypersensitivity to oxymorphone, morphine analogs such as codeine, or any ingredient in the formulation.^b ^c ^d

Respiratory depression in the absence of resuscitative equipment.^b ^c ^d

Acute or severe asthma or hypercarbia.^b ^c ^d

Known or suspected paralytic ileus.^b ^c ^d

Moderate or severe hepatic impairment.^b ^c ^d

Extended-release preparation contraindicated in the management of immediate postoperative pain (first 12–24 hours following surgery), in patients with mild pain, and in those who are expected to require analgesia for a short period of time.^c

Parenteral use contraindicated in the treatment of pulmonary edema resulting from a chemical respiratory irritant.^d

Warnings/Precautions

Warnings

Dependence and Abuse

Possible tolerance, psychologic dependence, and physical dependence following prolonged administration.^b ^c Use only with careful surveillance in patients with a history of drug or alcohol dependence or abuse.^b ^c Clinicians should consider abuse potential when prescribing or dispensing oxymorphone in situations where they are concerned about an increased risk of misuse, abuse, or diversion.^d However, concerns about abuse, addiction, and diversion should not prevent the proper management of pain.^c ^d

Oxymorphone tablets can be abused by crushing, chewing, “snorting” the powder, or dissolving the contents in water and injecting.^c ^d

Breaking, chewing, or crushing of extended-release tablets results in immediate release of the opiate and the risk of a potentially fatal overdose.^c (See Boxed Warning.)

Abrupt cessation of therapy or sudden reduction in dosage after prolonged use may result in withdrawal symptoms.^b ^c ^d After prolonged exposure to opiate analgesics, if withdrawal is necessary, it must be undertaken gradually.^b ^c ^d

Health-care professionals should contact the professional licensing board or controlled substance authority in their states for information about prevention and detection of abuse or diversion.^c ^d

Respiratory Depression

The major toxicity associated with oxymorphone.^c ^d ^e

Occurs most frequently in geriatric or debilitated patients and in those with conditions accompanied by hypoxia or hypercapnia when even moderate therapeutic opiate dosages may dangerously decrease pulmonary ventilation.^c ^d ^e

Use with extreme caution in patients with hypoxia, hypercapnia, or substantially decreased respiratory reserve (e.g., asthma, COPD, cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, coma).^c ^d ^e In such patients, even therapeutic oxymorphone doses may decrease respiratory drive while simultaneously increasing airway resistance to the point of apnea.^c ^d ^e Consider use of non-opiate analgesics.^c ^d ^e Use oxymorphone only with careful medical supervision and at lowest effective dosage.^c ^d ^e

Interactions with Other CNS Depressants

Additive depressant effects may occur with concomitant use of other CNS depressants including other opiates, sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, illicit drugs associated with CNS depression, and alcohol.^c ^d ^e (See Specific Drugs under Interactions.)

Hypoventilation, hypotension, and profound sedation or coma may occur.^c ^d ^e

Head Injury and Increased Intracranial Pressure

Respiratory depressant effects of oxymorphone (with CO₂ retention and secondary elevation of CSF pressure) may be markedly exaggerated in the presence of head injury, other intracranial lesions, or preexisting increase in intracranial pressure.^c ^d ^e

Opiates produce effects (e.g., pupillary changes) that may obscure neurologic signs of further increase in pressure in patients with head injuries.^c ^d ^e

Hypotensive Effects

Possible severe hypotension in individuals whose ability to maintain their BP is compromised by depleted blood volume or concomitant drugs that compromise vasculature tone (e.g., phenothiazines, general anesthetics).^b ^c ^d ^e

Use with caution in patients in circulatory shock, because vasodilation produced by the drug may further reduce cardiac output and BP.^b ^c ^d

General Precautions

Acute Abdominal Conditions

Administration may complicate assessment of patients with acute abdominal conditions.^b ^c ^d (See GI Effects under Cautions.)

Seizures

May aggravate preexisting seizures in patients with seizure disorders.^c ^d ^e May induce seizures.^b ^c ^d

Debilitated and Special-Risk Patients.

Use with caution in debilitated patients, those sensitive to CNS depressants, patients with Addison’s disease, CNS depression or coma, kyphoscoliosis, myxedema or hypothyroidism, prostatic hypertrophy, urethral stricture, severe impairment of pulmonary function, toxic psychosis, acute alcoholism, delirium tremens, or following GI surgery.^b ^c ^d

Pancreatic and Biliary Disease

May cause spasm of the sphincter of Oddi.^b ^c ^d Use with caution in patients with biliary tract disease, including acute pancreatitis, and patients undergoing biliary tract surgery.^b ^c ^d

GI Effects

Monitor for decreased bowel motility in post-operative patients.^b ^c ^d (See Acute Abdominal Conditions under Cautions.)

Contraindicated in patients with known or suspected paralytic ileus.^b ^c ^d

Specific Populations

Pregnancy

Category C.^b ^c ^d

Use parenteral preparation with caution during labor.^d Administration during labor may cause neonatal respiratory depression.^d An opiate antagonist and resuscitative equipment for reversal of opiate-induced respiratory depression should be readily available when opiates are administered during labor and delivery.^d

Use of oxymorphone tablets and extended-release tablets not recommended during or immediately prior to labor.^b ^c

Infants born to women regularly taking opiates during pregnancy may be physically dependent.^b ^c ^d

Lactation

Not known whether oxymorphone is distributed into human milk.^b ^c ^d Women receiving oxymorphone generally should not nurse.^b ^c ^d

Pediatric Use

Safety and efficacy not established in pediatric patients <18 years of age.^b ^c ^d

Geriatric Use

No substantial difference in efficacy of oral preparations in geriatric patients relative to younger adults.^b ^c Dizziness, somnolence, confusion, nausea reported more frequently in geriatric adults than in younger adults.^b ^c

Following oral administration, plasma concentrations of oxymorphone are higher in geriatric patients ≥65 years of age than in younger patients.^b ^c ^d (See Special Populations under Pharmacokinetics.)

Parenteral preparation not systematically evaluated in geriatric adults.^d

Select dose with caution, starting at the low end of the dosing range, because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.^b ^c ^d

Hepatic Impairment

Use with caution in patients with mild hepatic impairment.^b ^c ^d (See Hepatic Impairment under Dosage and Administration.)

Contraindicated in patients with moderate or severe hepatic impairment.^b ^c ^d

Renal Impairment

Use with caution in patients with moderate or severe renal impairment.^b ^c ^d Dosage adjustment needed in these patients.^b ^c ^d (See Renal Impairment under Dosage and Administration and see Special Populations under Pharmacokinetics.)

Common Adverse Effects

Nausea, constipation, pyrexia, somnolence, vomiting, pruritus, headache, dizziness, confusion.^b ^c ^d

Interactions for Oxymorphone Hydrochloride

Specific Drugs

Drug	Interaction	Comments
Alcohol	Additive CNS effects^b ^c ^d Oxymorphone extended-release tablets: Increased or decreased plasma oxymorphone concentrations reported^c	Avoid concomitant use^b ^c
Anticholinergic agents	Increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus^b ^c ^d
Cimetidine	Adverse CNS effects (confusion, disorientation, respiratory depression, apnea, seizures) reported with opiates^b ^c ^d	Caution^b ^c ^d
CNS depressants (e.g., opiate agonists, general anesthetics, tranquilizers, phenothiazines, sedatives/hypnotics)	Additive CNS effects.^b ^d	Reduce dosage of one or both agents; initiate oxymorphone therapy using (1/3) to ½ the usual dose^b ^c ^d
MAO inhibitors		Use with caution^b ^c ^d
Opiate partial agonists (butorphanol, buprenorphine, nalbuphine, pentazocine)	Possible reduced analgesic effect and/or withdrawal symptoms^b ^c ^d	Avoid concomitant use^b ^c ^d

Oxymorphone Hydrochloride Pharmacokinetics

Absorption

Bioavailability

Absolute oral bioavailability is 10%.^b ^c

Onset

5–10 minutes following IV administration.^a ^d

10–15 minutes following sub-Q or IM administration.^a

Duration

3–6 hours following parenteral administration.^a ^d

Food

Conventional tablets with high-fat meal: Peak plasma concentration and AUC increase 38%.^b

Extended-release tablets with food: Peak plasma concentrations increase 50%; time to peak plasma concentrations delayed; no change in AUC or small increase.^c

Special Populations

Oxymorphone extended-release tablets: Bioavailability increased 26, 57, or 65% in patients with mild (Cl_cr 51–80 mL/minute), moderate (Cl_cr 30–50 mL/minute), or severe renal impairment (Cl_cr <30 mL/minute), respectively.^c

Oxymorphone extended-release tablets: Based on information from a few individuals with hepatic impairment, bioavailability increased 1.6-, 3.7-, or 12.2-fold in patients with mild, moderate, or severe hepatic impairment, respectively.^c

Oxymorphone extended-release tablets: Plasma concentrations increased 40% in geriatric individuals.^c

Distribution

Plasma Protein Binding

10–12%.^b ^c

Elimination

Metabolism

Extensively metabolized in the liver; undergoes reduction or conjugation with glucuronic acid to form oxymorphone-3-glucuronide and 6-OH-oxymorphone.^b ^c ^d

Elimination Route

33–38% excreted in the urine as oxymorphone-3-glucuronide, <1% excreted in urine as 6-OH-oxymorphone, <1% excreted unchanged in the urine.^b ^c ^d

Half-life

Extended-release tablets: 9.4–11.3 hours.^c

Stability

Storage

Oral

Conventional Tablets

Tight container at 25°C (may be exposed to 15–30°C).^b

Extended-release Tablets

Tight container at 25°C (may be exposed to 15–30°C).^c

Parenteral

Injection

25°C (may be exposed to 15°–30°C).^d Protect from light.^d

ActionsActions

A potent analgesic; shares the actions of the opiate agonists.^b ^c ^d

Precise mechanism of action has not been fully elucidated; opiate agonists act at several CNS sites, involving several neurotransmitter systems to produce analgesia.^e

Pain perception is altered in the spinal cord and higher CNS levels (e.g., substantia gelatinosa, spinal trigeminal nucleus, periaqueductal gray, periventricular gray, medullary raphe nuclei, hypothalamus).^e

Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli, nor peripheral nerve impulse conduction.^e

Opiate agonists act at specific receptor binding sites in the CNS and other tissues; opiate receptors are concentrated in the limbic system, thalamus, striatum, hypothalamus, midbrain, and spinal cord.^e

Agonist activity at the opiate μ- or κ-receptor can result in analgesia, miosis, and/or decreased body temperature.^e

Agonist activity at the μ-receptor can also result in suppression of opiate withdrawal (and antagonist activity can result in precipitation of withdrawal).^e

Respiratory depression may be mediated by μ-receptors, possibly μ₂-receptors (which may be distinct from μ₁-receptors involved in analgesia); κ- and δ-receptors may also be involved in respiratory depression.^e

Advice to Patients

Importance of not breaking, crushing, or chewing extended-release tablets; potentially fatal overdose can occur.^c

Conventional and extended-release tablets: Advise patients to take tablets on an empty stomach, at least 1 hour before or 2 hours after food.^b ^c

Importance of taking only as prescribed; do not increase dosage or abruptly discontinue without consulting a clinician.^b ^c ^d

Advise patients to report any episodes of breakthrough pain or adverse experiences to their clinician.^b ^c ^d

Advise patients that oxymorphone should not be combined with alcohol or other CNS depressants (e.g., sleep medications, tranquilizers).^b ^c ^d

Potential for severe constipation.^b ^c ^d Counsel patients on appropriate laxatives and/or stool softeners and other therapeutic approaches.^b ^c ^d

Importance of informing patients that oxymorphone may impair mental and/or physical ability required for performance of potentially hazardous tasks; avoid driving or operating heavy machinery until effects on individual are known.^b ^c ^d

Risk of dizziness and other adverse events.^b ^c ^d

Importance of informing patients that this is a drug of potential abuse and should be protected from theft.^b ^c ^d

Importance of informing patients that this medication should never be given to anyone other than the individual for whom it was prescribed.^b ^c ^d

Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.^b ^c ^d

Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.^b ^c ^d

Importance of informing patients of other important precautionary information.^b ^c ^d (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Oxymorphone hydrochloride is subject to control under the Federal Controlled Substances Act of 1970 as a schedule II (C-II) drug.

Oxymorphone Hydrochloride
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Tablets	5 mg	Opana ( C-II)	Endo
		10 mg	Opana ( C-II)	Endo
	Tablet, extended-release	5 mg	Opana ER ( C-II)	Endo
		10 mg	Opana ER ( C-II)	Endo
		20 mg	Opana ER ( C-II)	Endo
		40 mg	Opana ER ( C-II)	Endo
Parenteral	Injection	1 mg/mL	Opana ( C-II; preservative-free)	Endo

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 04/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Opana 5MG Tablets (ENDO PHARMACEUTICALS): 20/$71.99 or 30/$105.97

Opana ER 10MG 12-hr Tablets (ENDO PHARMACEUTICALS): 20/$81.99 or 30/$122.98

Opana ER 15MG 12-hr Tablets (ENDO PHARMACEUTICALS): 20/$114.99 or 30/$170.97

Opana ER 20MG 12-hr Tablets (ENDO PHARMACEUTICALS): 20/$143.99 or 30/$214.97

Opana ER 40MG 12-hr Tablets (ENDO PHARMACEUTICALS): 20/$248.98 or 30/$372.97

Opana ER 5MG 12-hr Tablets (ENDO PHARMACEUTICALS): 20/$47.99 or 30/$71.98

Opana ER 7.5MG 12-hr Tablets (ENDO PHARMACEUTICALS): 20/$65.99 or 30/$93.99

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

References

a. AHFS drug information 2007. McEvoy GK, ed. Oxymorphone. Bethesda, MD: American Society of Health-System Pharmacists; 2007: 2154-5.

b. Endo Pharmaceuticals Inc. Opana (oxymorphone hydrochloride) tablets prescribing information. Chadds Ford, PA; 2006 Jul.

c. Endo Pharmaceuticals Inc. Opana ER (oxymorphone hydrochloride) extended-release tablets prescribing information. Chadds Ford, PA; 2007 June.

d. Endo Pharmaceuticals Inc. Opana (oxymorphone hydrochloride) injection prescribing information. Chadds Ford, PA; 2006 Sept.

e. AHFS drug information 2007. McEvoy GK, ed. Opioid Agonists General Statement. Bethesda, MD: American Society of Health-System Pharmacists; 2007:2123-8.

More Oxymorphone Hydrochloride resources

Oxymorphone Hydrochloride Side Effects (in more detail)
Oxymorphone Hydrochloride Use in Pregnancy & Breastfeeding
Drug Images
Oxymorphone Hydrochloride Drug Interactions
Oxymorphone Hydrochloride Support Group
107 Reviews for Oxymorphone Hydrochloride - Add your own review/rating

Oxymorphone Prescribing Information (FDA)

Oxymorphone MedFacts Consumer Leaflet (Wolters Kluwer)

Opana MedFacts Consumer Leaflet (Wolters Kluwer)

Opana Prescribing Information (FDA)

Opana Advanced Consumer (Micromedex) - Includes Dosage Information

Opana Consumer Overview

Opana ER Prescribing Information (FDA)

Opana ER Extended-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Oxymorphone Hydrochloride with other medications

Labor Pain
Pain

Tuesday, March 3, 2009

Famodar

Famodar may be available in the countries listed below.

Ingredient matches for Famodar

Famotidine

Famotidine is reported as an ingredient of Famodar in the following countries:

Bahrain

Iraq

Lebanon

Libya

Nigeria

Oman

Romania

Saudi Arabia

Somalia

Sudan

Tunisia

Yemen

International Drug Name Search

Sunday, March 1, 2009

Baza-Pro

Generic Name: topical emollients (TOP i kal ee MOL i ents)

Brand Names: Aloe Vesta Cream, AlphaSoft, AmeriPhor, Aqua Glycolic, Aqua Lube, Aquaphor, Aveeno, Baby Lotion, Baby Oil, Bag Balm, Baza-Pro, Beta Care, Blistex Lip Balm, Carmex, CarraKlenz, CeraVe, CeraVe AM, Cetaphil Lotion, Chap Stick, Citraderm, CoolBottoms, Corn Huskers Lotion, Curel Moisture Lotion, Derma Soothe, Dr Scholl's Essentials Cracked Skin Repair, Eucerin, Herpecin-L, K-Y Jelly, Keri Lotion, Lamisilk Heel Balm, Lubri-Soft, Lubriderm, Mederma, Moisturel, Natural Ice, NeutrapHor, NeutrapHorus Rex, Neutrogena Cleansing, Neutrogena Lotion, Nivea, Nutraderm, Pacquin, Phisoderm, Pretty Feet & Hands, Proshield Skincare Kit, Remedy 4-in-1 Cleansing Lotion, Replens, Secura, Sensi-Care, Soft Sense, St. Ives, Theraplex Lotion, Vaseline Intensive Care

What are Baza-Pro (topical emollients)?

Emollients are substances that moisten and soften your skin.

Topical (for the skin) emollients are used to treat or prevent dry skin. Topical emollients are sometimes contained in products that also treat acne, chapped lips, diaper rash, cold sores, or other minor skin irritation.

There are many brands and forms of topical emollients available and not all are listed on this leaflet.

Topical emollients may also be used for purposes not listed in this medication guide.

What is the most important information I should know about Baza-Pro (topical emollients)?

You should not use a topical emollient if you are allergic to it. Topical emollients will not treat or prevent a skin infection.

Ask a doctor or pharmacist before using this medication if you have deep wounds or open sores, swelling, warmth, redness, oozing, bleeding, large areas of skin irritation, or any type of allergy.

What should I discuss with my healthcare provider before using Baza-Pro (topical emollients)?

You should not use a topical emollient if you are allergic to it. Topical emollients will not treat or prevent a skin infection.

Ask a doctor or pharmacist if it is safe for you to use this medicine if you have:

deep wounds or open sores;

swelling, warmth, redness, oozing, or bleeding;

large areas of skin irritation;

any type of allergy; or

if you are pregnant or breast-feeding.

How should I use Baza-Pro (topical emollients)?

Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.

Clean the skin where you will apply the topical emollient. It may help to apply this product when your skin is wet or damp. Follow directions on the product label.

Shake the product container if recommended on the label.

Apply a small amount of topical emollient to the affected area and rub in gently.

If you are using a stick, pad, or soap form of topical emollient, follow directions for use on the product label.

Do not use this product over large area of skin. Do not apply a topical emollient to a deep puncture wound or severe burn without medical advice.

If your skin appears white or gray and feels soggy, you may be applying too much topical emollient or using it too often.

Some forms of topical emollient may be flammable and should not be used near high heat or open flame, or applied while you are smoking.

Store as directed away from moisture, heat, and light. Keep the bottle, tube, or other container tightly closed when not in use.

What happens if I miss a dose?

Since this product is used as needed, it does not have a daily dosing schedule. Seek medical advice if your condition does not improve after using a topical emollient.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Baza-Pro (topical emollients)?

Avoid getting topical emollients in your eyes, nose, or mouth. If this does happen, rinse with water. Avoid exposure to sunlight or tanning beds. Some topical emollients can make your skin more sensitive to sunlight or UV rays.

Baza-Pro (topical emollients) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using the topical emollient and call your doctor if you have severe burning, stinging, redness, or irritation where the product was applied.

Less serious side effects are more likely, and you may have none at all.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Baza-Pro (topical emollients)?

It is not likely that other drugs you take orally or inject will have an effect on topically applied products. But many drugs can interact with each other. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More Baza-Pro resources

Baza-Pro Use in Pregnancy & Breastfeeding
Baza-Pro Support Group
0 Reviews for Baza-Pro - Add your own review/rating

Biafine Emulsion MedFacts Consumer Leaflet (Wolters Kluwer)

Campath Monograph (AHFS DI)

Campral Monograph (AHFS DI)

Camptosar Monograph (AHFS DI)

Diabinese Monograph (AHFS DI)

Kinerase Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Neosalus Foam MedFacts Consumer Leaflet (Wolters Kluwer)

Promiseb Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Baza-Pro with other medications

Dry Skin

Where can I get more information?

Your pharmacist can provide more information about topical emollients.

Flasicox

Flasicox may be available in the countries listed below.

Ingredient matches for Flasicox

Meloxicam

Meloxicam is reported as an ingredient of Flasicox in the following countries:

Indonesia

International Drug Name Search

Sunday, March 22, 2009

Ingredient matches for Enison

Ingredient matches for Gliquidon LPH

Saturday, March 14, 2009

Ingredient matches for Cypafly

Thursday, March 12, 2009

Ingredient matches for Adofen

Monday, March 9, 2009

Commonly used brand name(s)

Uses For Burnamycin

Before Using Burnamycin

Allergies

Pediatric

Geriatric

Pregnancy

Breast Feeding

Interactions with Medicines

Interactions with Food/Tobacco/Alcohol

Other Medical Problems

Proper Use of lidocaine

Precautions While Using Burnamycin

Burnamycin Side Effects

More Burnamycin Topical resources

Compare Burnamycin Topical with other medications

Sunday, March 8, 2009

Commonly used brand name(s)

Uses For Dermarest

Before Using Dermarest

Allergies

Pediatric

Geriatric

Interactions with Medicines

Interactions with Food/Tobacco/Alcohol

Other Medical Problems

Proper Use of hydrocortisone

Dosing

Missed Dose

Storage

Precautions While Using Dermarest

Dermarest Side Effects

More Dermarest resources

Compare Dermarest with other medications

Saturday, March 7, 2009

Dermarest Cream is used for:

Do NOT use Dermarest Cream if:

Before using Dermarest Cream:

How to use Dermarest Cream:

Important safety information:

Possible side effects of Dermarest Cream:

If OVERDOSE is suspected:

General information:

More Dermarest resources

Compare Dermarest with other medications

Friday, March 6, 2009

Introduction

Uses for Oxymorphone Hydrochloride

Acute and Chronic Pain

Surgery

Analgesia During Labor

Acute Pulmonary Edema

Oxymorphone Hydrochloride Dosage and Administration

Administration

Oral Administration

IV Administration

Dosage

Adults

Pain (Oral Treatment)

Conventional Tablets

Switching from Parenteral Oxymorphone to Conventional Tablets

Extended-release Tablets

Switching from Conventional Oxymorphone Tablets to Extended-release Tablets

Switching from Parenteral Oxymorphone to Extended-release Tablets

Switching from Other Oral Opiates to Extended-release Tablets

Pain (Parenteral Routes)

IV

Sub-Q or IM

Analgesia During Labor

Prescribing Limits

Adults

Oral